Claims
- 1. A peptide having the amino acid sequence X-Ser-Ser-Ser-Gly-Arg-Met-Ile-Met-Glu-Lys-Gly-Glu-Ile-Lys-Asn-Cys-Ser -Phe-Asn-Ile-Ser-Thr-Ser-Y wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group.
- 2. A peptide having the amino acid sequence X-Gly-Glu-Ile-Lys-Asn-Cys-Ser-Phe-Asn-Ile-Ser-Thr-Ser-Ile-Arg-Gly-Lys -Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Y wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group.
- 3. A peptide having the amino acid sequence X-Ile-Arg-Gly-Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Tyr-Lys-Leu-Asp-Ile -Ile-Pro-Ile-Asp-Asn-Asp-Thr-Thr-Ser-Tyr-Thr-Y wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group.
- 4. A peptide having the amino acid sequence X-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Ala-Pro-Ala-Gly -Phe-Ala-Ile-Leu-Lys-Cys-Asn-Asn-Y wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group.
- 5. A peptide having the amino acid sequence X-Cys-Gly-Gly-Glu-Phe-Phe-Tyr-Cys-Asn-Ser-Thr-Gln-Leu-Phe-Asn-Ser-Thr -Trp-Phe-Asn-Ser-Thr-Trp-Y wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group.
- 6. A composition for the activation of T cells against human immunodeficiency virus comprising:
- (a) an amount of a peptide sufficient to elicit T cell activation, the peptide having the amino acid sequence:
- X-Ser-Ser-Ser-Gly-Arg-Met-Ile-Met-Glu-Lys-Gly-Glu-Ile-Lys-Asn-Cys -Ser-Phe-Asn-Ile-Ser-Thr-Ser-Y,
- wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group; and
- (b) a physiologically acceptable carrier therefor.
- 7. A composition for the activation of T cells against human immunodeficiency virus comprising:
- (a) an amount of a peptide sufficient to elicit T cell activation, the peptide having the amino acid sequence:
- X-Gly-Glu-Ile-Lys-Asn-Cys-Ser-Phe-Asn-Ile-Ser-Thr-Ser-Ile-Arg-Gly -Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Y,
- wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group; and
- (b) a physiologically acceptable carrier therefor.
- 8. A composition for the activation of T cells against human immunodeficiency virus comprising:
- (a) an amount of a peptide sufficient to elicit T cell activation, the peptide having the amino acid sequence:
- X-Ile-Arg-Gly-Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Tyr-Lys-Leu-Asp -Ile-Ile-Pro-Ile-Asp-Asn-Asp-Thr-Thr-Ser-Tyr-Thr-Y,
- wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group; and
- (b) a physiologically acceptable carrier therefor.
- 9. A composition for the induction of IL-2 production comprising:
- (a) an amount of a peptide sufficient to elicit IL-2 production, the peptide having the amino acid sequence:
- X-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Ala-Pro-Ala -Gly-Phe-Ala-Ile-Leu-Lys-Cys-Asn-Asn-Y,
- wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by a hydroxy group; and
- (b) a physiologically acceptable carrier therefor.
- 10. A composition for the activation of T cells against human immunodeficiency virus comprising:
- (a) an amount of a peptide sufficient to elicit T cell activation, the peptide having the amino acid sequence:
- X-Cys-Gly-Gly-Glu-Phe-Phe-Tyr-Cys-Asn-Ser-Thr-Gln-Leu-Phe-Asn-Ser -Thr-Trp-Phe-Asn-Ser-Thr-Trp-Y,
- wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group; and
- (b) a physiologically acceptable carrier therefor.
- 11. A composition for the activation of T cells against human immunodeficiency virus comprising:
- (a) an amount of at least two peptides sufficient to elicit T cell activation, wherein the peptides are selected from the amino acid sequences: ##STR2## wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group; and
- (b) a physiologically acceptable carrier therefor.
Parent Case Info
This application is a continuation of patent application Ser. No. 07/709,709, filed Jun. 3, 1991, which is a continuation-in-part of U.S. patent application Ser. No. 07/571,080, filed Aug. 22, 1990, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4943628 |
Rosen et al. |
Jul 1990 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
273716 |
Dec 1987 |
EPX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
709709 |
Jun 1991 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
571080 |
Aug 1990 |
|